다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

ENLV Enlivex Therapeutics Ltd

1.42

-0.03 (-2.07%)

16 5월(5) 2024 - 마감

Yet Another Biotech Stock Has Found Success During Tuesday's Session

It appears to be the day for biotechs as yet another company in the space has caught our attention during Tuesday’s session. Earlier in the day, an Illinois-based biotech...

To read the full story on AllPennyStocks.com, click here.

Enlivex Therapeutics (NASDAQ:ENLV)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024

Enlivex Therapeutics 차트를 더 보려면 여기를 클릭.

Enlivex Therapeutics (NASDAQ:ENLV)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024

Enlivex Therapeutics 차트를 더 보려면 여기를 클릭.

Enlivex Therapeutics Ltd News

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
0년 29월 4일, 2024 (2 주 전) • GlobeNewswire Inc.

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
0년 22월 4일, 2024 (3 주 전) • GlobeNewswire Inc.

Yet Another Biotech Stock Has Found Success During Tuesday's Session
0년 17월 4일, 2024 (4 주 전) • AllPennyStocks.com

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
0년 16월 4일, 2024 (4 주 전) • GlobeNewswire Inc.

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
0년 12월 4일, 2024 (1 월 전) • GlobeNewswire Inc.

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
0년 11월 4일, 2024 (1 월 전) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 7월 2일, 2024 (3 월 전) • Edgar (US Regulatory)

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
0년 7월 2일, 2024 (3 월 전) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 22월 1일, 2024 (4 월 전) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 17월 1일, 2024 (4 월 전) • Edgar (US Regulatory)

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
0년 17월 1일, 2024 (4 월 전) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 20월 12일, 2023 (5 월 전) • Edgar (US Regulatory)

More Enlivex Therapeutics Ltd News Articles

Energy Select Sector SPDR

US Dollar vs Yen

Health Care Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관